tbuckley/cabot-search huggingface dataset:
Predicting cardiac adverse events in patients receiving immune checkpoint inhibitors: a machine learning approach
Authors: Samuel Peter Heilbroner, Reed Few, Tomas G Neilan, Judith Mueller, Jitesh Chalwa, Francois Charest, Somasekhar Suryadevara, Christine Kratt, Andres Gomez-Caminero, Brian Dreyfus
Journal: Journal for ImmunoTherapy of Cancer (2021)

Background Treatment with immune checkpoint inhibitors (ICIs) has been associated with an increased rate of cardiac events. There are limited data on the risk factors that predict cardiac events in patients treated with ICIs. Therefore, we created a machine learning (ML) model to predict cardiac events in this at-risk population. Methods We leveraged the CancerLinQ database curated by the American Society of Clinical Oncology and applied an XGBoosted decision tree to predict cardiac events in patients taking programmed death receptor-1 (PD-1) or programmed death ligand-1 (PD-L1) therapy. All curated data from patients with non-small cell lung cancer, melanoma, and renal cell carcinoma, and who were prescribed PD-1/PD-L1 therapy between 2013 and 2019, were used for training, feature interpretation, and model performance evaluation. A total of 356 potential risk factors were included in the model, including elements of patient medical history, social history, vital signs, common laboratory tests, oncological history, medication history and PD-1/PD-L1-specific factors like PD-L1 tumor expression. Results Our study population consisted of 4960 patients treated with PD-1/PD-L1 therapy, of whom 418 had a cardiac event. The following were key predictors of cardiac events: increased age, corticosteroids, laboratory abnormalities and medications suggestive of a history of heart disease, the extremes of weight, a lower baseline or on-treatment percentage of lymphocytes, and a higher percentage of neutrophils. The final model predicted cardiac events with an area under the curve–receiver operating characteristic of 0.65 (95% CI 0.58 to 0.75). Using our model, we divided patients into low-risk and high-risk subgroups. At 100 days, the cumulative incidence of cardiac events was 3.3% in the low-risk group and 6.1% in the high-risk group (p&lt;0.001). Conclusions ML can be used to predict cardiac events in patients taking PD-1/PD-L1 therapy. Cardiac risk was driven by immunological factors (eg, percentage of lymphocytes), oncological factors (eg, low weight), and a cardiac history.
26P Structurally constrained tumor-specific epitope within the largest extracellular domain of sodium-dependent phosphate transporter NaPi2b
Authors: L.F. Bulatova, V. Skripova, A. Nurgalieva, D. Reshetnikova, D.V. Savenkova, A. Timonina, M.V. Bogdanov, R.G. Kiyamova
Journal: Annals of Oncology (2021)
Determinants of tumor resistance to anti-angiogenic immunotherapy in mouse models of Krasmutant NSCLC.
Authors: Amaia Martinez-Usatorre, Ece Kadioglu, Chiara Cianciaruso, Alan Guichard, Bruno Torchia, Sina Nassiri, Martina Schmittnaegel, Carola H. Ries, Etienne Meylan, Ioanna Keklikoglou, Michele De Palma
Journal: Cancer Research (2021)
1246P A phase I dose-escalation study of mobocertinib (TAK-788), an oral tyrosine kinase inhibitor (TKI), in Japanese NSCLC patients
Authors: T. Hida, M. Nishino, K. Yoh, T. Asato, T. Kitagawa, S. Zhang, M. Mehta, Y. Ohe
Journal: Annals of Oncology (2021)
Renal Aplastic Dysplasia and Ipsilateral Ectopic Ureter Obstructing the Seminal Via: A Possible Cause of Male Infertility: Part 2
Authors: Antonio Carbone, Giovanni Palleschi, Giulio Tomiselli, Maurizio Inghilleri, Rocco Rago, Andrea Lenzi, Antonio Luigi Pastore
Journal: European Urology (2007)
Poor In Utero Growth, and Reduced β-Cell Compensation and High Fasting Glucose From Childhood, Are Harbingers of Glucose Intolerance in Young Indians
Authors: Chittaranjan S. Yajnik, Souvik Bandopadhyay, Aboli Bhalerao, Dattatray S. Bhat, Sanat B. Phatak, Rucha H. Wagh, Pallavi C. Yajnik, Anand Pandit, Sheila Bhave, Kurus Coyaji, Kalyanaraman Kumaran, Clive Osmond, Caroline H.D. Fall
Journal: Diabetes Care (2021)

OBJECTIVE India is a double world capital of early-life undernutrition and type 2 diabetes. We aimed to characterize life course growth and metabolic trajectories in those developing glucose intolerance as young adults in the Pune Maternal Nutrition Study (PMNS). RESEARCH DESIGN AND METHODS PMNS is a community-based intergenerational birth cohort established in 1993, with serial information on parents and children through pregnancy, childhood, and adolescence. We compared normal glucose-tolerant and glucose-intolerant participants for serial growth, estimates of insulin sensitivity and secretion (HOMA and dynamic indices), and β-cell compensation accounting for prevailing insulin sensitivity. RESULTS At 18 years (N = 619), 37% of men and 20% of women were glucose intolerant (prediabetes n = 184; diabetes n = 1) despite 48% being underweight (BMI &amp;lt;18.5 kg/m2). Glucose-intolerant participants had higher fasting glucose from childhood. Mothers of glucose-intolerant participants had higher glycemia in pregnancy. Glucose-intolerant participants were shorter at birth. Insulin sensitivity decreased with age in all participants, and those with glucose intolerance had consistently lower compensatory insulin secretion from childhood. Participants in the highest quintile of fasting glucose at 6 and 12 years had 2.5- and 4.0-fold higher risks, respectively, of 18-year glucose intolerance; this finding was replicated in two other cohorts. CONCLUSIONS Inadequate compensatory insulin secretory response to decreasing insulin sensitivity in early life is the major pathophysiology underlying glucose intolerance in thin rural Indians. Smaller birth size, maternal pregnancy hyperglycemia, and higher glycemia from childhood herald future glucose intolerance, mandating a strategy for diabetes prevention from early life, preferably intergenerationally.
1065P A retrospective multicenter Italian analysis of the effect of longer vismodegib intake in 68 basal cell carcinoma patients who achieved clinical complete remission
Authors: S. Alfieri, S. Marceglia, D.M. Filippini, C. Bergamini, C. Resteghini, S. Cavalieri, K. Peris, P. Sollena, A. Piccerillo, G. Gualdi, P.A. Ascierto, M. Curvietto, M. Palla, V. De Giorgi, L. Eibenschutz, F. Spagnolo, E. Orlandi, L.D. Locati, L.F. Licitra, P. Bossi
Journal: Annals of Oncology (2021)
1296P Immune checkpoint inhibitors with or without bone targeted therapy in NSCLC patients with bone metastases and prognostic significance of neutrophil-to-lymphocyte ratio
Authors: A. Bongiovanni, F. Foca, J. Menis, L.S. Stucci, F. Artioli, V. Guadalupi, M.R.C. Forcignanò, M. Fantini, F. Recine, L. Mercatali, C. Spadazzi, A. De Vita, R. Casadei, M.C. Falasconi, V. Fausti, M.C. Pallotti, M. Bertoni, S. Vanni, T. Ibrahim
Journal: Annals of Oncology (2021)
Specific T cells targeting <i>Staphylococcus aureus</i> fibronectin‐binding protein 1 induce a type 2/type 1 inflammatory response in sensitized atopic dermatitis patients
Authors: Ahmed K. Farag, Lennart M. Roesner, Susanne Wieschowski, Annice Heratizadeh, Britta Eiz‐Vesper, William W. Kwok, Rudolf Valenta, Thomas Werfel
Journal: Allergy (2021)

Atopic dermatitis (AD) is one of the most common inflammatory skin diseases worldwide and Staphylococcus aureus colonization and secondary infections occur in the majority of AD patients. Allergic sensitizations against microbial antigens have been discussed as possible trigger factors of AD. Recently, we reported IgE sensitization against fibronectin-binding protein 1 (FBP1), an essential virulence component in S. aureus, in a subgroup of patients suffering from AD. To expand these findings by investigating delayed-type immune reactions, the objective of this study was to detect and phenotypically characterize FBP1-specific T cells as possible trigger factors in AD.
Motivational Interviewing and the Use of Psychological Services Among Youth With Chronic Medical Conditions
Authors: Marie-Eve Robinson
Journal: JAMA Network Open (2021)

Christina Reinauer, MD; Anna Lena Platzbecker, MSc; Rabea Viermann, MSc; Matthias Domhardt, MSc; Harald Baumeister, PhD; Katharina Foertsch; Hannah Linderskamp, MD; Lisa Krassuski, BA; Doris Staab, MD; Kirsten Minden, MD; Reinhold Kilian, PhD; Reinhard W. Holl, MD, PhD; Petra Warschburger, PhD; Thomas Meißner, MD
Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia
Authors: Melissa B. Pappalardi, Kathryn Keenan, Mark Cockerill, Wendy A. Kellner, Alexandra Stowell, Christian Sherk, Kristen Wong, Sarath Pathuri, Jacques Briand, Michael Steidel, Philip Chapman, Arthur Groy, Ashley K. Wiseman, Charles F. McHugh, Nino Campobasso, Alan P. Graves, Emma Fairweather, Thilo Werner, Ali Raoof, Roger J. Butlin, Lourdes Rueda, John R. Horton, David T. Fosbenner, Cunyu Zhang, Jessica L. Handler, Morris Muliaditan, Makda Mebrahtu, Jon-Paul Jaworski, Dean E. McNulty, Charlotte Burt, H. Christian Eberl, Amy N. Taylor, Thau Ho, Susan Merrihew, Shawn W. Foley, Anna Rutkowska, Mei Li, Stuart P. Romeril, Kristin Goldberg, Xing Zhang, Christopher S. Kershaw, Marcus Bantscheff, Anthony J. Jurewicz, Elisabeth Minthorn, Paola Grandi, Mehul Patel, Andrew B. Benowitz, Helai P. Mohammad, Aidan G. Gilmartin, Rab K. Prinjha, Donald Ogilvie, Christopher Carpenter, Dirk Heerding, Stephen B. Baylin, Peter A. Jones, Xiaodong Cheng, Bryan W. King, Juan I. Luengo, Allan M. Jordan, Ian Waddell, Ryan G. Kruger, Michael T. McCabe
Journal: Nature Cancer (2021)
1033TiP A first-in-human phase I study of FS120, an OX40/CD137 tetravalent bispecific antibody, in patients with advanced malignancies
Authors: K. Papadopoulos, T.A. Yap, S.A. Piha-Paul, P. Lorusso, S. Hu-Lieskovan, C.J. Shepherd, S. Marshall, J-B. Holz, E. Poon, U.B. Grabowska, L. Kayitalire
Journal: Annals of Oncology (2021)
1451P An onco-palliative expertise unit in a French comprehensive cancer center: Experience at 2 years
Authors: P. Renard, C. Mateus, A. Sampetrean, L. Vigouret-Viant, S. Voisin, E. Pavliuc, S. Laurent, F. Scotté, S. Dauchy
Journal: Annals of Oncology (2021)
788P Circulating human papillomavirus DNA as a biomarker of response in advanced cervical cancer
Authors: M. McMullen, L. Avery, J. Zou, Z. Zhao, A. Tesfu, N. Dhani, A.M. Oza, H. Kathy, S.V. Bratman, S. Lheureux
Journal: Annals of Oncology (2021)
Dual‐Light‐Triggered In Situ Structure and Function Regulation of Injectable Hydrogels for High‐Efficient Anti‐Infective Wound Therapy
Authors: Yu Zhang, Haixia Wu, Peipei Li, Wenxin Liu, Yanling Zhang, Alideertu Dong
Journal: Advanced Healthcare Materials (2021)

Abstract Most injectable hydrogels used in biomedical engineering have unsatisfactory and untunable mechanical properties, making it difficult to match them with the mechanical strengths of different tissues and organs, which can cause a series of adverse consequences such as immune rejection and soft tissue contusion. In this contribution, dopamine‐modified hyaluronic acid (HA‐DA) is developed as the backbone for an injectable hydrogel using a catechol–Fe 3+ coordination crosslinking strategy. Due to dynamic physical crosslinking, the hydrogel can be easily injected through a single syringe. Into the hydrogel, black phosphorous nanosheets loaded with a Zr‐based porphyrinic metal−organic framework (PCN@BP) are introduced that could generate reactive oxygen species (ROS) under 660 nm laser irradiation, this promotes the oxidative coupling of dopamine in the presence of the ROS, introducing in situ chemical crosslinking into the hydrogel. A physical/chemical double‐crosslinked hydrogel is obtained, effectively improving the hydrogel's mechanical properties, which are tuned in situ by adjusting the irradiation time to match the mechanical modulus of different biological tissues. Combining the excellent photothermal properties and photodynamic performance of the PCN@BP nanosheets yields effective sterilization under mild conditions (below 50 °C, low ROS production). The results show that this hydrogel is an excellent multifunctional wound dressing.
1758O Neoadjuvant pembrolizumab in localized/locally advanced solid tumors with mismatch repair deficiency
Authors: K. Ludford, K. Raghav, M.A. Blum Murphy, N.D. Fleming, D. Nelson, M.S. Lee, B.G. Smaglo, Y.N. You, M.M. Tillman, C. Kamiya-Matsuoka, S. Thirumurthi, C. Messick, B. Johnson, E. Vilar, J. Thomas, W.C. Foo, W. Qiao, S. Kopetz, M.J. Overman
Journal: Annals of Oncology (2021)
Effects of Lifestyle Modification on Patients With Resistant Hypertension: Results of the TRIUMPH Randomized Clinical Trial
Authors: James A. Blumenthal, Alan L. Hinderliter, Patrick J. Smith, Stephanie Mabe, Lana L. Watkins, Linda Craighead, Krista Ingle, Crystal Tyson, Pao-Hwa Lin, William E. Kraus, Lawrence Liao, Andrew Sherwood
Journal: Circulation (2021)

Although lifestyle modifications generally are effective in lowering blood pressure (BP) among patients with unmedicated hypertension and in those treated with 1 or 2 antihypertensive agents, the value of exercise and diet for lowering BP in patients with resistant hypertension is unknown.One hundred forty patients with resistant hypertension (mean age, 63 years; 48% female; 59% Black; 31% with diabetes; 21% with chronic kidney disease) were randomly assigned to a 4-month program of lifestyle modification (C-LIFE [Center-Based Lifestyle Intervention]) including dietary counseling, behavioral weight management, and exercise, or a single counseling session providing SEPA (Standardized Education and Physician Advice). The primary end point was clinic systolic BP; secondary end points included 24-hour ambulatory BP and select cardiovascular disease biomarkers including baroreflex sensitivity to quantify the influence of the baroreflex on heart rate, high-frequency heart rate variability to assess vagally mediated modulation of heart rate, flow-mediated dilation to evaluate endothelial function, pulse wave velocity to assess arterial stiffness, and left ventricular mass to characterize left ventricular structure.Between-group comparisons revealed that the reduction in clinic systolic BP was greater in C-LIFE (-12.5 [95% CI, -14.9 to -10.2] mm Hg) compared with SEPA(-7.1 [-95% CI, 10.4 to -3.7] mm Hg) (P=0.005); 24-hour ambulatory systolic BP also was reduced in C-LIFE (-7.0 [95% CI, -8.5 to -4.0] mm Hg), with no change in SEPA (-0.3 [95% CI, -4.0 to 3.4] mm Hg) (P=0.001). Compared with SEPA, C-LIFE resulted in greater improvements in resting baroreflex sensitivity (2.3 ms/mm Hg [95% CI, 1.3 to 3.3] versus -1.1 ms/mm Hg [95% CI, -2.5 to 0.3]; P<0.001), high-frequency heart rate variability (0.4 ln ms2 [95% CI, 0.2 to 0.6] versus -0.2 ln ms2 [95% CI, -0.5 to 0.1]; P<0.001), and flow-mediated dilation (0.3% [95% CI, -0.3 to 1.0] versus -1.4% [95% CI, -2.5 to -0.3]; P=0.022). There were no between-group differences in pulse wave velocity (P=0.958) or left ventricular mass (P=0.596).Diet and exercise can lower BP in patients with resistant hypertension. A 4-month structured program of diet and exercise as adjunctive therapy delivered in a cardiac rehabilitation setting results in significant reductions in clinic and ambulatory BP and improvement in selected cardiovascular disease biomarkers. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02342808.
The Significance of PARP1 as a biomarker for Predicting the Response to PD-L1 Blockade in Patients with PBRM1-mutated Clear Cell Renal Cell Carcinoma
Authors: Masayuki Hagiwara, Atsushi Fushimi, Kazuhiro Matsumoto, Mototsugu Oya
Journal: European Urology (2021)
1721P Patients with advanced cancer referred to a supportive care team (SCT) from a multidisciplinary tumor board (MTB): Symptom burden and its relationship with MTB treatment decision
Authors: F.R. Djordjevic, M. Calamac, S.M. Bosnjak, J. Dimitrijevic, A. Zilic, S. Susnjar, V. Stankovic, N. Lazin, N. Bakic
Journal: Annals of Oncology (2021)
Reverted exhaustion phenotype of circulating lymphocytes as immune correlate of anti-PD1 first-line treatment in Hodgkin lymphoma
Authors: Maria A. Garcia-Marquez, Martin Thelen, Sarah Reinke, Diandra Keller, Kerstin Wennhold, Jonas Lehmann, Johanna Veldman, Sven Borchmann, Andreas Rosenwald, Stephanie Sasse, Arjan Diepstra, Peter Borchmann, Andreas Engert, Wolfram Klapper, Michael von Bergwelt-Baildon, Paul J. Bröckelmann, Hans A. Schlößer
Journal: Leukemia (2021)

Abstract While classical Hodgkin lymphoma (HL) is highly susceptible to anti-programmed death protein 1 (PD1) antibodies, the exact modes of action remain controversial. To elucidate the circulating lymphocyte phenotype and systemic effects during anti-PD1 1st-line HL treatment we applied multicolor flow cytometry, FluoroSpot and NanoString to sequential samples of 81 HL patients from the NIVAHL trial (NCT03004833) compared to healthy controls. HL patients showed a decreased CD4 T-cell fraction, a higher percentage of effector-memory T cells and higher expression of activation markers at baseline. Strikingly, and in contrast to solid cancers, expression for 10 out of 16 analyzed co-inhibitory molecules on T cells (e.g., PD1, LAG3, Tim3) was higher in HL. Overall, we observed a sustained decrease of the exhausted T-cell phenotype during anti-PD1 treatment. FluoroSpot of 42.3% of patients revealed T-cell responses against ≥1 of five analyzed tumor-associated antigens. Importantly, these responses were more frequently observed in samples from patients with early excellent response to anti-PD1 therapy. In summary, an initially exhausted lymphocyte phenotype rapidly reverted during anti-PD1 1st-line treatment. The frequently observed IFN-y responses against shared tumor-associated antigens indicate T-cell-mediated cytotoxicity and could represent an important resource for immune monitoring and cellular therapy of HL.
759P Adding dosing of plasmid encoding p62/SQSTM1 to gemcitabine chemotherapy may provide clinical benefits to patients with platinum-resistant ovarian cancer
Authors: S. Polyakov, S. Krasny, E. Zhavrid, Y. Baranau, O. Sergeeva, K. Zharkova, A. Khorau, S. Kozlovskaya, V. Gabai, A. Shneider
Journal: Annals of Oncology (2021)
1317P Renal toxicity in black patients with non-squamous non-small cell lung cancer treated with combination platinum-pemetrexed-pembrolizumab therapy
Authors: N. Balanchivadze, Z. Nasser, M. Shahid, C. Mckay, P. Li, R. Sohaney, S.M. Gadgeel
Journal: Annals of Oncology (2021)
557TiP SGNTUC-019: Phase II basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations
Authors: M. Reck, A. Okines, P.R. Pohlmann, E. Yu, T. Bekaii-Saab, Y. Nakamura, B.J. Monk, D. O'Malley, V. Kang, L.N. Walker, T. Stinchcombe
Journal: Annals of Oncology (2021)
1281O Atezolizumab (atezo) vs platinum-based chemo in blood-based tumour mutational burden-positive (bTMB+) patients (pts) with first-line (1L) advanced/metastatic (m)NSCLC: Results of the Blood First Assay Screening Trial (BFAST) phase III cohort C
Authors: R. Dziadziuszko, S. Peters, S.M. Gadgeel, M.S. Mathisen, S.M. Shagan, E. Felip, A. Morabito, P. Cheema, M. Cobo Dols, Z. Andric, C.H. Barrios, M. Yamaguchi, E. Dansin, P. Danchaivijitr, M. Johnson, S. Novello, D.R. Gandara, E. Schleifman, J. Wang, T.S.K. Mok
Journal: Annals of Oncology (2021)
1601P SARS-CoV-2 serological response in cancer patients in the Principality of Andorra (COVONCO study)
Authors: C. Royo-Cebrecos, I. Ambatlle, Ï. Robert, J.M. Buldon, D. Vilanova, J. Serrano Pons, E. Baillés, E. Mahia, J. Pujadas olano, F. Cobo, S. Albiol Rodriguez
Journal: Annals of Oncology (2021)
1580P Impact of COVID-19 infection on breast cancer patients: Experience in Latin-American country ACHOCC-19B study
Authors: A.V. Ospina Serrano, R. Bruges, W. Mantilla, I. Triana, P. Ramos, S. Aruachan, A. Quiroga, I. Munevar, J. Ortiz, N. Llinas, P. Pinilla, H. Vargas, H. Idrobo, A. Russi, R. Manneh, G. Rivas, H. Gonzalez, D. Santa, J. Insuasty, L. Bernal
Journal: Annals of Oncology (2021)
Nosocomial outbreak caused by the SARS-CoV-2 Delta variant in a highly vaccinated population, Israel, July 2021
Authors: Pnina Shitrit, Neta S Zuckerman, Orna Mor, Bat-Sheva Gottesman, Michal Chowers
Journal: Eurosurveillance (2021)

A nosocomial outbreak of SARS-CoV-2 Delta variant infected 42 patients, staff and family members; 39 were fully vaccinated. The attack rate was 10.6% (16/151) among exposed staff and reached 23.7% (23/97) among exposed patients in a highly vaccinated population, 16-26 weeks after vaccination (median: 25 weeks). All cases were linked and traced to one patient. Several transmissions occurred between individuals wearing face masks. Fourteen of 23 patients became severely sick or died, raising a question about possible waning immunity.
Leveraging external data in the design and analysis of clinical trials in neuro-oncology
Authors: Rifaquat Rahman, Steffen Ventz, Jon McDunn, Bill Louv, Irmarie Reyes-Rivera, Mei-Yin C Polley, Fahar Merchant, Lauren E Abrey, Joshua E Allen, Laura K Aguilar, Estuardo Aguilar-Cordova, David Arons, Kirk Tanner, Stephen Bagley, Mustafa Khasraw, Timothy Cloughesy, Patrick Y Wen, Brian M Alexander, Lorenzo Trippa
Journal: The Lancet Oncology (2021)
Associations of Maternal Serum Perfluoroalkyl Substances Concentrations with Early Adolescent Bone Mineral Content and Density: The Health Outcomes and Measures of the Environment (HOME) Study
Authors: Jessie P. Buckley, Jordan R. Kuiper, Bruce P. Lanphear, Antonia M. Calafat, Kim M. Cecil, Aimin Chen, Yingying Xu, Kimberly Yolton, Heidi J. Kalkwarf, Joseph M. Braun
Journal: Environmental Health Perspectives (2021)

Per- and polyfluoroalkyl substances (PFAS) may impair bone accrual and strength via endocrine disruption and nuclear receptor agonism, but human studies are primarily of adults or cross-sectional. We assessed associations of individual PFAS and their mixture during pregnancy with child bone mineral content (BMC) and areal bone mineral density (aBMD) at age 12 y. Among 206 mother-child pairs enrolled in a prospective cohort (2003-2006), we quantified perfluorooctanoic acid (PFOA), perfluorononanoic acid (PFNA), perfluorohexane sulfonic acid (PFHxS), and perfluorooctane sulfonic acid (PFOS) in maternal serum collected during gestation or delivery. When children were age 12 y, we performed dual energy X-ray absorptiometry and calculated BMC, aBMD, and bone mineral apparent density (BMAD) z-scores for six skeletal sites. We estimated covariate-adjusted z-score differences per doubling of individual PFAS using linear regression and assessed the PFAS mixture using quantile g-computation and Bayesian kernel machine regression. We explored whether associations were modified by child's sex or mediated by whole-body lean mass. In covariate-adjusted models, we found that higher maternal serum concentrations of PFOA, PFNA, and the PFAS mixture were associated with lower total hip and forearm (one-third distal radius) BMC z-scores in children. Differences in forearm BMC z-scores were -0.17 [95% confidence interval (CI): -0.35, 0.01] and -0.24 (95% CI: -0.44, -0.05) per doubling of PFOA and PFNA, respectively, and -0.18 (95% CI: -0.34, -0.02) per quartile increase in the PFAS mixture. Child's sex modified PFOA associations for some skeletal sites; for example, differences in spine BMAD z-score per doubling were -0.31 (95% CI: -0.58, -0.03) among males and 0.07 (95% CI: -0.16, 0.30) among females (modification p=0.04). Except for PFNA among females, these associations were not mediated by whole-body lean mass. Maternal PFAS concentrations during pregnancy may be associated with lower bone mineral accrual and strength in early adolescence. https://doi.org/10.1289/EHP9424.
1476P Is it worth adding concurrent chemo-radiotherapy or radiotherapy on the top of neoadjuvant chemotherapy in the management of borderline resectable and locally advanced pancreatic adenocarcinoma? A systematic review
Authors: A. Saha, J. Wadsley, B. Sirohi, R. Goody, D. Ulahannan, D. Wilson, F. Collinson, A. Anthony
Journal: Annals of Oncology (2021)